Key result
Elevated plasma levels of PAPP-A and IGF-1 were independently associated with increased ASCVD risk and the requirement for revascularization.
Why the study?
Little is known about the significance of plasma PAPP-A and IGF-1 levels as biomarkers of ASCVD risk and their association with the need for revascularization.
Are plasma levels of PAPP-A and IGF-1 associated with increased ASCVD risk and the need for revascularization in patients presenting to the catheterization lab?
Observational
Are plasma levels of PAPP-A and IGF-1 associated with increased ASCVD risk and the need for revascularization in patients presenting to the catheterization lab?
Plasma levels of PAPP-A and IGF-1 correlate with ASCVD risk and disease severity, suggesting their potential utility as biomarkers to identify patients likely to require revascularization.
BACKGROUND: The pregnancy associated plasma protein A (PAPP-A) is present at high levels in serum of pregnant women with a potential role in atherosclerosis. PAPP-A is a metalloproteinase with a well-established role in releasing bioactive insulin-like growth factor-1 (IGF-1). Little is known about their significance as biomarkers of Atherosclerotic cardiovascular diseases (ASCVDs) risk and their association with the need of revascularization through percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG). AIMS: To evaluate plasma levels of PAPP-A and IGF-1 in patients with increased ASCVDs risk and examine if they are associated with CAD severity as indicated by the need for revascularization. METHODS: Patients presented to the catheterization lab were grouped based on ASCVDs risk into low, moderate, high, and very high. Plasma levels of PAPP-A and IGF-1 were assessed using ELISA and correlated with ASCVDs risk and the requirement for revascularization. RESULTS: Plasma PAPP-A and IGF-1 levels were increased in CAD patients, with elevated concentrations in MI patients. A stepwise elevation in plasma PAPP-A and IGF-1 levels was observed with the elevated ASCVDs risk. An independent association was observed between plasma PAPP-A and IGF-1 levels, ASCVDs risk, and the requirement for revascularization. CONCLUSION: Our study demonstrates that plasma levels of PAPP-A and IGF-1 are associated with elevated ASCVDs risk and may serve as potential biomarkers for monitoring disease development. Their association with disease severity suggests a potential role in identifying patients more likely to undergo revascularization, pending further prospective validation.
No takes yet. Share an insight, caveat, or question.
Mayyas et al. (2026) conducted an observational in Atherosclerotic cardiovascular diseases (ASCVD). Elevated plasma levels of PAPP-A and IGF-1 vs. Lower ASCVD risk or non-CAD patients was evaluated on Association with ASCVD risk and requirement for revascularization. Elevated plasma levels of PAPP-A and IGF-1 were independently associated with increased ASCVD risk and the requirement for revascularization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: